Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Editas Medicine reported second quarter 2026 financial results on August 5, 2026, showing a net loss of $18.2 million (or $0.15 per share), a significant improvement from a net loss of $53.2 million (or $0.63 per share) in the same quarter of 2025.

Collaboration and other research and development revenue increased to $11.9 million for Q2 2026, up from $3.6 million in Q2 2025, largely driven by recognition of deferred revenue following the expiration of certain rights under its collaboration with Bristol Myers Squibb.

Cash and cash equivalents stood at $211.6 million as of June 30, 2026, up from $146.6 million at December 31, 2025; the company expects this cash position to fund its operations and capital expenditures into the second half of 2028.

Research and development expenses rose to $20.2 million in Q2 2026 from $16.2 million in Q2 2025 due to higher external spending primarily on EDIT-401, while general and administrative expenses declined year over year to $11.6 million, reflecting lower employee-related and professional services costs following workforce reductions and the discontinuation of the reni-cel program.

The company highlighted progress on EDIT-401, its lead in vivo gene editing program, noting robust preclinical data in non-human primates and plans to submit a Clinical Trial Notification in Australia in August 2026 and initiate a Phase 1/2 trial in patients with heterozygous familial hypercholesterolemia in 2026, with an expected data update in the first quarter of 2027.